Federal Register / Vol. 70, No. 86 / Thursday, May 5, 2005 / Notices 23881 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Pacific Proving Grounds 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services gives notice as required 

by 42 CFR 83.12(e) of a decision to 

evaluate a petition to designate a class 

of employees at the Pacific Proving 

Grounds, to be included in the Special 

Exposure Cohort under the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000. The 

initial proposed definition for the class 

being evaluated, subject to revision as 

warranted by the evaluation, is as 

follows: 

Facility: Pacific Proving Grounds, 

Marshall Islands. 

Locations: Enewetak Atoll. 

Job Titles and/or Job Duties: All 

scientists and scientific couriers. 

Period of Employment: July 1, 1958, 

until August 31, 1958 (Operation 

Hardtack I). 

FOR FURTHER INFORMATION CONTACT: 

Larry Elliott, Director, Office of 

Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health, 4676 Columbia 

Parkway, MS C–46, Cincinnati, OH 

45226, telephone 513–533–6800 (this is 

not a toll-free number). Information 

requests can also be submitted by e-mail 

to ocas@cdc.gov. 

Dated: April 28, 2005. 

James D. Seligman, 

Associate Director for Program Services, 

Centers for Disease Control and Prevention. 

[FR Doc. 05–8949 Filed 5–4–05; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Use of Human Papilloma 

Virus (HPV) Immunoreactive Peptides 

for the Development of Vaccines 

Against HPV Infections 

AGENCY: National Institutes of Health, 

Public Health Service, DHHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

license to practice the invention 

embodied in: 

PCT/US02/09261 filed March 22, 2002, 

entitled ‘‘Human Papilloma Virus 

Immunoreactive Peptides’’ (E–126–2001/0– 

PCT–02), (Inventors: Samir N. Khleif and Jay 

Berzofsky) (NCI), prior U.S. provisional 

application 60/278,520, filed March 23, 2001, 

now abandoned. National stage filed March 

22, 2002: In U.S. Patent Application No. 10/ 

472,661; in Canada Patent Application No. 

2,441,947; in EPO Patent Application No. 

02728570.9; in Australia Patent Application 

No. 2002258614 to Panacea Biotec Ltd. 

(hereafter PBL), having a place of business in 

New Deli, India. The patent rights in these 

inventions have been assigned to the United 

States of America. 

DATES: Only written comments and/or 

application for a license, which are 

received by the NIH Office of 

Technology Transfer on or before July 5, 

2005 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application, inquiries, comments 

and other materials relating to the 

contemplated license should be directed 

to: Sally Hu, Ph.D., M.B.A., Office of 

Technology Transfer, National Institutes 

of Health, 6011 Executive Boulevard, 

Suite 325, Rockville, MD 20852–3804; 

Email: hus@od.nih.gov; Telephone: 

(301) 435–5606; Facsimile: (301) 402– 

0220. 

SUPPLEMENTARY INFORMATION: PCT/ 

US02/09261 provides immunogenic 

peptides from the Human Papilloma 

Virus which are suitable for 

development of epitope-based vaccines 

directed towards HPV and discloses 

methods of administering these peptides 

to individuals, as well as a method for 

monitoring or evaluating an immune 

response to HPV with these peptides. 

This invention provides a potential 

prophylactic or therapeutic vaccine 

against cervical cancer caused by 

HPV16 and 18, and a targeted therapy 

for cervical cancer and other diseases 

that are caused by HPV including other 

genital cancers, head and neck cancers, 

and upper digestive tract cancers. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless, 

within 60 days from the date of this 

published Notice, NIH receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404.7. 

The field of use may be limited to the 

development of vaccines against HPV 

infections. 

Properly filed competing applications 

for a license filed in response to this 

notice will be treated as objections to 

the contemplated license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection, and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: April 26, 2005. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 05–8960 Filed 5–4–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the provision 

set forth in sections 552b(c)(4) and 

552b(c)(6), Title 5 U.S.C., as amended. 

The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel 

Review of Research Project Applications 

(R01s). 

Date: June 2–3, 2005. 

Time: 6:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Irina Gordienko, PhD, 

Review Branch, NIH, NHLBI, DEA, Bethesda, 

MD 20892, (301) 325–0725, 

gordieni@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS)